- Home
- FLC vs CHRS Comparison
FLC vs CHRS Comparison
Compare FLC & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FLC | CHRS |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.4M | 177.7M |
| IPO Year | 2003 | 2014 |
Fundamental Metrics
Financial Performance| Metric | FLC | CHRS |
|---|---|---|
| Price | $16.09 | $1.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.51 |
| AVG Volume (30 Days) | 27.8K | ★ 868.0K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 472.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $73.08 |
| Revenue Next Year | N/A | $30.94 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.89 | $1.09 |
| 52 Week High | $18.09 | $2.62 |
Technical Indicators
Market Signals| Indicator | FLC | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 28.28 | 48.79 |
| Support Level | $15.89 | $1.31 |
| Resistance Level | $17.00 | $1.51 |
| Average True Range (ATR) | 0.10 | 0.07 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 16.95 | 58.51 |
Price Performance
Historical ComparisonAbout FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.